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Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative syndrome 
in Western countries, and it is characterized by recurrent large genomic rearrangements. 
During the last decades, array techniques have expanded our knowledge about CLL’s 
karyotypic aberrations. The advent of large sequencing databases expanded our 
knowledge cancer genomics to an unprecedented resolution and enabled the detection of 
small-scale structural aberrations in the cancer genome. In this study, we have performed 
exome-sequencing-based copy number aberration (CNA) and loss of heterozygosity 
(LOH) analysis in order to detect new recurrent structural aberrations. We describe 54 
recurrent focal CNAs enriched in cancer-related pathways, and their association with 
gene expression and clinical evolution. Furthermore, we discovered recurrent large copy 
number neutral LOH events affecting key driver genes, and we recapitulate most of the 
large CNAs that characterize the CLL genome. These results provide “proof-of-concept” 
evidence supporting the existence of new genes involved in the pathogenesis of CLL.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative disease in 
Western populations, and it is characterized by its clinical and genetic heterogeneity. Döhner et al. 
(2000) described the widely used cytogenetic classification of CLL based on the most prevalent 
chromosomal aberrations in the CLL genome (Döhner et al., 2000), that is, trisomy 12 and deletions 
in 13q14.2–14.3, 11q22.3, and 17p13.1. Since that moment, new genome-wide studies have revealed 
new recurrent genomic aberrations, such as trisomy 19, amplifications at 2p and 8q, and deletions 
at 8p, 6q21, 18p, and 20p (Pfeifer et al., 2007; Landau et al., 2015). Similarly, a wealth of genomic 
and epigenomic modulators of CLL’s clinical aggressivity have been discovered (Nadeu et al., 2018), 
such as point mutations in NOTCH1, SF3B1, ATM, TP53, and POT1 and the absence of somatic 
hypermutation at the IGHV locus. It has been observed that copy number aberrations (CNAs) in 
CLL genomes tend to be acquired early in disease evolution and usually remain stable, whereas the 
mutational heterogeneity can increase (Nadeu et al., 2018). Indeed, mounting evidence indicates that 
the accumulation of these cytogenomic events modulates CLL proliferation and clinical aggressivity 
to a great extent (Raponi et al., 2018; Gruber et al., 2019), acting as drivers of genomic complexity 
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and clonal evolution (Edelmann et al., 2017; Yu et  al., 2017; 
Hernández-Sánchez et al., 2019) and accumulating in relapsed 
cases (Ljungström et al., 2016; Leeksma et al., 2019).
CNAs and copy number neutral loss of heterozygosity (CNN-
LOH) are oncogenic mechanisms that induce gene-dosage effects, 
disrupt coding sequences, cause structural rearrangements, or 
potentiate epigenetic effects. Oncogenes are frequently affected 
by copy number gains, while tumor suppressor genes tend to be 
deleted. Massive array-based techniques such as array comparative 
genomic hybridization and single-nucleotide polymorphism 
(SNP) arrays have enabled the analysis of structural aberrations 
on cancer genomes to an unprecedented resolution of 10–100 
kb. With the development of massive sequencing technologies, 
large databases of cancer sequence data have been published. 
This motivated the development of a variety of CNA detection 
algorithms from exome-sequencing data, which have the 
additional benefit of detecting smaller CNA events at the expense 
of increased false discoveries and reduced sensitivity and specificity 
(Nam et al., 2016). These methods are specifically designed to face 
particular issues, particularly those inherent to the sequencing 
protocol (such as biases induced by hybridization, GC content, and 
read mappability), due to cancer biology (ploidy estimation and 
subclonality) (Zare et al., 2017) and due to the presence or absence 
of matched controls (Kim et al., 2017).
In this analysis, we used previously published exome-seq data 
in order to detect small recurrent structural events involved in the 
pathogenesis of CLL. Our results not only reproduce the known 
cytogenetic aberrations in CLL but also support the existence 
of multiple recurrent focal CNAs and CNN-LOH affecting key 
oncogenic pathways, some of which are clearly associated with 
higher proliferative capacity, shorter survival, and altered gene 
expression. We conclude that focal CNAs may be more relevant 
than previously expected in the pathogenesis of CLL, and they 
merit further consideration for prognostic stratification.
METHODOLOGY
Data Source
The International Cancer Genome Consortium (ICGC) Data 
Access Committee granted us access to the CLL sequencing data 
(Ramsay et al., 2013) deposited in the European Genome-Phenome 
Database (EGA) under DACO-1040945. For this analysis, we 
used exome-seq data from matched control and tumor samples 
of CLL cases under the accession code EGAD00001001464. 
Patient characteristics can be consulted in Table 1.
Data Preprocessing
Samples were processed by Puente et al. (2015) as described in 
their original paper (Puente et al., 2015). Briefly, 3 μg of genomic 
DNA was used for paired-end sequencing library construction, 
followed by enrichment in exomic sequences using the SureSelect 
Human All Exon 50Mb kit (Agilent Technologies). Next, DNA was 
pulled down using magnetic beads with streptavidin, followed 
by 18 cycles of amplification. Sequencing was performed on an 
Illumina GAIIx or on a HiSeq2000 sequencer (2 × 76 bp). Exome-
seq data were aligned to the reference genome (GRCh37.75) 
using bwa (Li and Durbin, 2009). Duplicate read removal, 
sorting, and indexing were done using samtools (Li et al., 2009). 
Base quality score recalibration was made with BamUtil (Breese 
and Liu, 2013) using a logistic regression model.
CNA and CNN-LOH Detection
We analyzed paired tumor-normal exome-sequencing data with 
Control-FREEC version 11.3 in order to identify somatic CNA 
and CNN-LOH regions (Boeva et al., 2012). Control-FREEC 
uses aligned reads to construct and normalize a copy number 
profile and a B-allele frequency (BAF) profile. Then, it performs 
profile segmentation and infers genotype status for each segment 
using both copy number and allelic frequency information. 
Finally, genomic aberrations are identified and annotated.
The following specifications were used: “window = 0,” 
“ploidy = 2,” “breakPointThreshold = 1.2,” “noisyData = TRUE,” 
“readCountThreshold = 50,” “forceGContentNormalization = 1,” 
“contaminationAdjustment = TRUE,” “telocentromeric = 50000,” 
and “mateOrientation = 0.” BAFs were estimated using all variants 
reported in dbSNP (version 150) with a minimal coverage per 
variant position of 5 reads and a minimal sequencing quality 
per position of 20 Phred. Variant calling was limited to regions 
covered in the SureSelect Exome Capture 50Mb version 4 kit.
LOH and CNA Selection and Filtering
CNN-LOH were called with p-values < 0.05 (Kolmogorov–
Smirnov test) and an uncertainty upper threshold of 5%. Regions 
with lowmappability according to UCSC 75-bp mappability 
tracks (score below 0.5) were filtered out. As expected, we 
observed regions that seemed prone to CNA erroneous detection. 
Thus, we decided to apply a hard filter and discard those CNAs 
significantly enriched in both amplifications and deletions, as 
well as those located near a telomeric or centromeric region. CNA 
events were detected using GISTIC2.0 (Beroukhim et al., 2007). 
GITIC2.0 was run with default parameters plus the arm peel-off 
filter. Focal recurrent CNAs were defined as those spanning less 
than 50% of a chromosome arm with a residual q-value < 0.05 
and a wide peak size below 10 megabases. A 1 − log2 tumor/
normal ratio above 0.3 was used to define amplifications, and a 
ratio below −0.3 was used to define deletions.
Survival Analysis
Variables associated with time to treatment (TTT) and overall 
survival (OS) were analyzed using Cox regression as implemented 
TABLE 1 | Patient characteristics.
Patient characteristics
Number of cases 441
Males/females 59.7%/40.3%
Median age at diagnosis 62.5 years
% of MBL 11.20%
% of Binet A 77.12%
% of Binet B 9.61%
% of Binet C 2.06%
% unmutated IGHV 35.03%
MBL, monoclonal B-cell lymphocytosis.
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in the survival R package (Therneau and Grambsch, 2000; 
R Development Core Team, 2011; Therneau, 2015). Assessment 
of the proportional hazards assumption was performed using the 
cox.zph function. We created two different models: a univariate 
model that only includes CNA status for each gene and an 
adjusted model that included variables associated with clinical 
outcome at a p-value < 0.2 in a univariate model. The combined 
model (CM) for TTT analysis included as covariates donor sex, 
stage at diagnosis (monoclonal B-cell lymphocytosis (MBL), 
Binet A, Binet B, and Binet C), and IGHV mutational status, 
while the CM for OS analysis included stage at diagnosis, IGHV 
mutation status, and age at diagnosis. The Benjamini–Hochberg 
(BH) method was used to adjust for multiple testing.
RNAseq Analysis and Correlation 
With CNA Status
Two hundred twenty patients had matched RNAseq data 
of CLL-purified cells (accession IDs EGAD00001001443 
and EGAD00001000258). Illumina adapters were removed 
using cutadapt (Martin, 2011), and alignment to the human 
reference genome (GRCh37) was performed using Hisat2 (Kim 
et al., 2015) with default specifications. We used the Hisat2-
provided Hierarchical Graph FM index for GRCh37 with SNP 
and Ensembl transcript information. Bam files were sorted 
and indexed using samtools (Li et al., 2009). Bam files were 
processed in R (R Development Core Team, 2011) according to 
the RNAseq gene expression protocol developed by Love et  al. 
(2015). Briefly, bam files were read using Rsamtools (Morgan 
et al., 2017), followed by gene-level expression estimation using 
the SummarizeOverlaps function from the GenomicAlignments 
package (Lawrence et al., 2013). Gene models in GTF format 
were downloaded from Ensembl (GRCh37.75 version) (Yates 
et al., 2016). A log2-transformation on normalized frames per 
kilobase counts was performed. Focal CNAs were classified 
according to Gistic into low-range events (tumor/normal log2 
ratio > 0.3 and <0.9 for amplifications and less than −0.9 and 
more than −0.3 for deletions) and higher-range events (tumor/
normal log2 ratio > 0.9 for amplifications and less than −0.9 for 
deletions). Correlation between CNA status and gene expression 
was performed using Spearman’s correlation. A minimum of 
5 CNA events with matched transcriptomic data was set for 
analysis. Furthermore, immunoglobulin and T-cell receptor gene 
rearrangements were not included. p-values were adjusted for 
multiple testing using the BH method.
RESULTS
Focal CNA Regions and Their Association 
With TTT and OS
We identified 54 recurrent focal CNAs in the CLL genome 
(residual q-value < 0.05, Supplemental Figure 1, Table 2). 
Among them, there were 31 recurrent amplifications with a wide 
peak size of 75.1 kb (Figure 1) and 23 recurrent deletions with a 
median wide peak size of 405 kb (Figure 2).
The most frequently amplified regions were found in 11p13 
(adjacent to the WT1 locus), 8q24.13 (FAM91A1), 3q25.1 (PFN2 
and RNF13), 18q22.1 (TMX3), 3q29 (ACAP2), 17q11.2 (SUZ12), 
14q32.33 (adjacent to the AKT1 locus), 13q13.3 (NBEA/BCL8B), 
1q25.2 (RFWD2), 5q35.3 (FLT4), 19p13.3 (adjacent to the APC2 
locus), 1p22.2 (HFM1), and 1p31.1. Similarly, the most recurrent 
focal deletions were detected in 13q14.2 (DLEU1 locus), 11q22.3 
(ATM locus), 14q21.1 (MIA2), 11q14.3 (NOX4), 14q32.33 (IGH 
locus), and 4q13.2 (UGT2B15 and UGT2B17 loci). Moreover, 
we observed frequent deletions of immunoglobulin loci and 
recurrent amplified regions at TCR genes, likely reflecting 
deletions present in the T lymphocytes within control samples.
Three focal deletions were associated with TTT (BH 
q-value < 0.05): 11q22.3 (ATM locus), 14q32.33 (IGH locus), 
and 7q21.2 (CDK6 locus). 11q22.3 loss was associated with 
shorter survival too. No event was associated with TTT or 
OS after adjusting for IGHV status, sex, and disease stage 
(BH q-value < 0.05). No recurrent gain was associated with 
treatment-free survival or OS. The association results can be 
consulted in Supplementary Table 1.
Furthermore, SETD2 deletions (nine cases) and IRF4 gains 
(five cases) were nearly significant (GISTIC residual q-values of 
0.08 and 0.06, respectively) and associated with clinical evolution. 
SETD2 deletion was associated with shorter treatment free 
survival (p-value 1.3 × 10−8) independent of IGHV status, sex, 
and disease stage (p-value 2.3 × 10−3); and it was also associated 
with shorter survival (p-value 9.9 × 10−3) but not independently 
of IGHV status (p-value 0.24). Amplifications in IRF4 were 
associated with shorter survival (p-value 6.4 × 10−5) in a partially 
IGHV-independent manner (p-value 0.025). Nevertheless, this 
finding must be interpreted with caution due to the position of 
IRF4 near the telomeric end of the short arm of chromosome 6.
Correlation of Focal CNAs With Gene 
Expression
We detected significant correlations between some recurrent 
CNAs and their correspondingly encoded genes (Supplementary 
Table 2). As expected, deletions in 11q22.3 and 13q14.2 and the 
expression of their respective genes (ATM, FDX1, and RDX in 
the first case, and DLEU1, DLEU2, and KCNRG in the second 
case). Deletions in 6q21 were correlated with lower expression 
of CDK19, and so did those in 14q21.1 with the expression 
of MIA2. Furthermore, we detected significant correlations 
between amplifications in 3q25.1 and 3q29 and expression of 
their target genes PFN2 and ACAP2, respectively. Surprisingly, 
an inverse correlation was observed between 11q14.3 deletions 
and FOLH1B expression.
Similarly, we detected significant correlations between 19 
of these CNAs and the expression of 926 protein-coding genes 
(q-value < 0.01; Supplementary Table 3). The CNAs with more 
correlated genes were deletions in 13q14.2 (389 genes), 12q24.33 
(ULK1 locus, 170 genes), 6q21 (CDK19 locus, 79 genes), 11q22.3 
(ATM locus, 39 genes), and 3q25.33 (IL12A locus, 26 genes), as 
well as amplifications in 18q22.1 involving TMX3 (135 genes).
Nonetheless, this study is probably underpowered to detect 
CNA–transcript correlations due to the fact that only 50% of 
the exome-seq samples had matched RNAseq data of purified 
CLL cells.
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TABLE 2 | Recurrent focal amplifications and deletions in the chronic lymphocytic leukemia (CLL) genome, including their frequency, wide peak region, length, q-value, 
residual q-value, and involved genes.
Unique Name Cases Cytoband Wide Peak Boundaries Length Q value Residual Q value Genes in Wide Peak
Amplification Peak 3 9 1p31.1 chr1:74500015–74621552 1.22E+05 4.80E−16 1.86E−11 LRRIQ3, FPGT, TNNI3K
Amplification Peak 4 9 1p22.2 chr1:91784576–91813183 2.86E+04 3.13E−11 5.32E−09 HFM1
Amplification Peak 8 11 1q25.2 chr1:176093431–176153873 6.04E+04 2.73E−13 8.89E−06 RFWD2
Amplification Peak 9 3 1q42.12 chr1:225152123–225211696 59,573 1.71E−03 1.71E−03 DNAH14
Amplification Peak 14 15 3q25.1 chr3:149563840–149684409 120,569 4.78E−04 1.92E−03 PFN2, RNF13
Amplification Peak 15 14 3q29 chr3:195053676–195063318 9.64E+03 1.01E−05 1.72E−05 ACAP2
Amplification Peak 17 6 4p16.3 chr4:3449609–3495293 45,684 9.11E−04 9.11E−04 HGFAC, DOK7
Amplification Peak 18 5 4p15.2 chr4:26622159–26641959 19,800 0.01 0.01 TBC1D19
Amplification Peak 19 5 4q31.21 chr4:145658875–146010087 351,212 5.17E−03 5.17E−03 ANAPC10, HHIP
Amplification Peak 20 10 5q35.3 chr5:180052785–180167076 1.14E+05 1.68E−05 1.68E−05 FLT4, OR2Y1
Amplification Peak 22 4 6q15 chr6:89479426–89563571 84,145 1.47E−04 1.47E−04 RNGTT
Amplification Peak 24 70 7p14.1 chr7:38284691–38357086 7.24E+04 1.62E−82 1.62E−82 TCRG locus
Amplification Peak 28 19 8q24.13 chr8:124810460–124812196 1,736 2.36E−03 0.02 FAM91A1
Amplification Peak 30 6 9q34.3 chr9:138905634–139092618 186,984 0.03 0.03 LHX3, C9orf69, NACC2
Amplification Peak 31 8 9q34.3 chr9:140161390–140246050 84,660 1.71E−03 1.71E−03 COBRA1, C9orf167, 
EXD3, NRARP
Amplification Peak 32 6 10q24.33 chr10:105073962–105140579 66,617 1.28E−04 1.28E−04 TAF5, PCGF6
Amplification Peak 33 26 11p13 chr11:32676388–32705141 2.88E+04 7.50E−13 5.84E−12 CCDC73, WT1
Amplification Peak 34 2 11p11.2 chr11:45935717–45955761 20,044 0.04 0.04 PEX16, PHF21A, 
GYLTL1B
Amplification Peak 40 11 13q13.3 chr13:35622613–35697715 75,102 5.17E−03 5.17E−03 NBEA
Amplification Peak 41 4 13q22.1 chr13:73530979–73643032 112,053 0.01 0.01 KLF5, PIBF1
Amplification Peak 42 188 14q11.2 chr14:22749319–22925867 1.77E+05 4.44E−186 2.84E−185 TCRA locus
Amplification Peak 45 12 14q32.33 chr14:105059814–105172511 1.13E+05 2.70E−05 4.01E−04 INF2, TMEM179, 
MIR4710, AKT1
Amplification Peak 50 8 16q22.1 chr16:66819728–66824959 5.23E+03 5.54E−05 5.54E−05 CCDC79, NAE1
Amplification Peak 51 12 17q11.2 chr17:30228618–30321772 9.32E+04 2.72E−20 2.23E−17 SUZ12, UTP6
Amplification Peak 53 6 17q25.3 chr17:79389937–79430022 40,085 0.02 0.02 hsa-mir-3186, BAHCC1, 
MIR3186
Amplification Peak 54 7 18q11.2 chr18:21229308–21329567 100,259 0.02 0.02 LAMA3, ANKRD29
Amplification Peak 55 15 18q22.1 chr18:66365105–66377388 12,283 0.03 0.03 TMX3
Amplification Peak 57 8 19p12 chr19:20221949–20317969 96,020 0.02 0.03 ZNF90, ZNF486
Amplification Peak 59 3 20q13.12 chr20:42694274–42813092 118,818 5.94E−03 5.94E−03 JPH2, TOX2
Amplification Peak 62 5 20q13.33 chr20:62705116–62831313 126,197 0.02 0.02 NPBWR2, MYT1, OPRL1, 
RGS19, C20orf201
Amplification Peak 66 4 22q13.33 chr22:50967459–51008050 40,591 1.39E−03 1.39E−03 CPT1B, TYMP, 
KLHDC7B, CHKB-
CPT1B, ODF3B, SYCE3
Deletion Peak 7 193 2p11.2 chr2:88894337–95722218 6,827,881 0 0 IGK locus
Deletion Peak 8 4 2q23.3 chr2:152234651–152663572 428,921 0.04 0.04 NEB, RIF1
Deletion Peak 13 12 3q25.33 chr3:159713418–160118695 405,277 0.02 0.04 IFT80, C3orf80, IL12A
Deletion Peak 16 19 4q13.2 chr4:69344747–69691521 3.47E+05 7.11E−06 3.92E−05 UGT2B15, UGT2B17
Deletion Peak 17 8 4q13.3 chr4:70897589–71020148 122,559 0.02 0.02 HTN1, CSN1S2AP, 
CSN1S2BP
Deletion Peak 18 9 4q21.23 chr4:84367119–84457735 90,616 1.71E−03 6.90E−03 MRPS18C, FAM175A
Deletion Peak 21 15 6q21 chr6:110797012–111583801 786,789 1.74E−04 1.74E−04 AMD1, CDK19, RPF2, 
GTF3C6, SLC16A10, 
GSTM2P1




Deletion Peak 24 11 7q21.2 chr7:92147625–92247368 9.97E+04 3.11E−05 9.98E−05 RBM48, MGC16142, 
FAM133B, LOC728066, 
CDK6
Deletion Peak 27 11 8q22.1 chr8:95690341–95840099 149,758 0.02 0.02 DPY19L4, ESRP1, 
TP53INP1
Deletion Peak 29 3 9p21.2 chr9:26116211–27109465 993,254 1.62E−03 1.62E−03 PLAA, LRRC19, C9orf82, 
IFT74, TEK
Deletion Peak 32 33 11q14.3 chr11:89185111–89443615 2.59E+05 1.36E−34 1.06E−22 FOLH1B, NOX4
Deletion Peak 34 44 11q22.3 chr11:110018375–110449975 4.32E+05 1.18E−31 1.13E−18 FDX1, RDX, ATM
(Continued)
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Broad CNA Regions and Their Association 
With Clinical Evolution
Recurrent broad amplifications and deletions were detected 
in the CLL genome (Table 3, Supplementary Figure 1). 
Among the amplifications, the most frequent were found 
in chromosomes 12 (60 cases, 13.6% of patients), 2p (10 
patients), 8q (6 patients), 18q (6 patients), 18p (5 patients), 
and 3q (5 patients). Similarly, the most recurrent large 
deletions were detected in 17p (8 patients), 18p (7 patients), 
and 8p (6 patients).
Amplifications in chromosomes 12, 2p, and 8q, as well as 
deletion of 17p, were significantly associated with shorter TTT 
(Supplementary Tables 4 and 5). Furthermore, deletion of 17p 
was significantly associated with TTT independently of IGHV 
status, sex, and Binet staging. Amplifications in chromosomes 
12 and 8q were associated with shorter OS, but no event was 
significant after adjusting for IGHV status, age, and Binet staging. 
Nonetheless, we detected a significant difference in OS and TTT 
between IGHV-mutated cases with and with and without trisomy 
12 (Figures 3A, B respectively).
Regions of CNN-LOH
Control-FREEC identified 63 regions of CNN-LOH with a 
genotype uncertainty below 5% (Supplementary Table 6). 
Ten events were located at 1p, six of which affected ARID1A. 
By comparing with mutation data published by Puente et  al. 
(2015), none of these samples bore concurrent non-synonymous 
mutations in ARID1A. Other three events were detected at 1q, 
with a minimally affected region on 1q21.3, which holds likely 
driver genes such as PI4KB and IL6R/CD126. Four CNN-LOH 
events with a minimally involved region in 9q34.13–q34.3 
involved the NOTCH1 gene. One of these cases also had a 
frameshift deletion in NOTCH1. Three events at 11p15.5–15.4 
affected the imprinted locus of IGF2 and CDKN1C. Eight CNN-
LOH events affected the 11p11.2–q13.2 region. Two different 
samples had events at 11q involving the ATM locus, both of 
which also had non-synonymous ATM mutations. Three events 
were located in 16p13.3–p13.11, which involve the CREBBP gene. 
None of these had mutations in CREBBP. Ten CNN-LOH events 
affected chromosome 17, three of which included the TP53 
locus. Among the latter, two had non-synonymous mutations in 
TP53. Four samples had CNN-LOH events at chromosome 20, 
all of which affect the ASXL1 gene but without any concurrent 
mutation in it. It is interesting to mention that only two of the 
CNN-LOH events overlapped with those reported by Puente et 
al. (2015) using SNP array technology.
DISCUSSION
The detection of new cytogenetic aberrations using targeted 
sequencing takes advantage of the increased sensitivity of 
this technique in order to detect small events that would be 
otherwise difficult to identify using array-based techniques. CLL 
is characterized by large-scale cytogenetic alterations (Döhner 
et  al., 2000), but focal rearrangements have been studied to a 
lower extent. Using sequencing data originally produced by 
Puente et al. (2015), here, we report the existence of 54 putatively 
recurrent focal CNAs in the CLL genome.
TABLE 2 | Continued
Unique Name Cases Cytoband Wide Peak Boundaries Length Q value Residual Q value Genes in Wide Peak
Deletion Peak 37 12 12q24.33 chr12:132335406–132436802 101,396 1.09E−03 1.05E−03 ULK1, PUS1






Deletion Peak 40 41 14q21.1 chr14:39721874–39871082 1.49E+05 1.56E−18 3.83E−10 CTAGE5, 
LOC100288846, MIA2, 
FBXO33
Deletion Peak 42 27 14q32.33 chr14:104506663–105201322 6.95E+05 1.61E−11 1.05E−03 hsa-mir-203, KIF26A, 
INF2, ASPG, TMEM179, 
C14orf180, MIR203, 
MIR3545, MIR4710





Deletion Peak 46 10 15q15.1 chr15:42138836–42192730 53,894 3.47E−03 0.01 hsa-mir-4310, SPTBN5, 
MIR4310
Deletion Peak 49 2 16q12.2 chr16:53968071–55360473 1,392,402 0.01 0.01 IRX5, IRX3, CRNDE
Deletion Peak 54 8 18q21.1 chr18:43604458–43796648 192,190 0.04 0.04 ATP5A1, HAUS1, 
PSTPIP2
Deletion Peak 55 10 18q23 chr18:77246915–77733812 486,897 2.64E−04 2.84E−04 CTDP1, KCNG2, PQLC1, 
HSBP1L1, NFATC1
Deletion Peak 66 125 22q11.22 chr22:23162356–23404171 2.42E+05 2.71E−277 5.01E−277 IGL locus
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Recurrent focal amplifications were shorter than deletions, 
mostly involving one or two genes. The most significantly 
enriched focal gains affected the loci of SUZ12, WT1, HFM1, 
RFWD2, FLT4, and TTNI3K. On the contrary, focal deletions 
were wider and tended to span more than two genes. As 
expected, among the most significant deletions were those in 
13q14.2 and in 11q22.3. Nevertheless, other highly significant 
regions involved the loci of genes such as NOX4, a component of 
the NADPH oxidase complex (Guo and Chen, 2015), and MIA2, 
a tumor suppressor gene (Hellerbrand et al., 2008). Deletions 
in SETD2, 11q22.3, and 14q32.33 were associated with shorter 
time to first treatment, and gains of IRF4 were independently 
associated with short survival. Furthermore, we could detect 
significant positive correlations between six recurrent CNAs and 
FIGURE 1 | Representation of the focal amplifications detected in the chronic lymphocytic leukemia (CLL) genomes along with their corresponding 
statistical significance.
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the expression of genes encoded in their respective loci, as well 
as correlations between 19 CNAs and the expression 926 protein-
coding genes genome wide.
Focal recurrent gains and losses tended to target genes that 
participate in oncogenic pathways. For example, five amplified 
genes (HFM1, ANAPC10, TAF5, COBRA1, and SYCE3) 
and one deleted gene (FAM175A/ABRAXAS) are involved 
in DNA transcription, replication, and repair mechanisms. 
Both COBRA1 and FAM175A physically interact with the 
tumor suppressor BRCA1 (Castillo et al., 2014; Yun et al., 
2018), whereas ANAPC10 belongs to the anaphase-promoting 
complex/cyclosome family of proteins that control sister 
chromatid segregation and cytokinesis (Chang et al., 2014). 
The amplified genes PHF21A, PCGF6, and SUZ12 encode 
FIGURE 2 | Representation of the focal deletions detected in the chronic lymphocytic leukemia (CLL) genomes along with their corresponding statistical 
significance.
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epigenetic regulators with repressor activity (Iwase et al., 2006; 
Vizán et  al., 2015; Zhao et al., 2017). Other genes targeted 
by recurrent events participate in important pathways. This 
is the case of the amplified oncogenes AKT1 (Hyman et al., 
2017) and WT1 (Bergmann et al., 1997), and of the receptor 
tyrosine kinase gene FLT4, which regulates lymphangiogenesis 
and tumor metastasization to lymphatic vessels (Lee et al., 
2016). Likewise, the deleted genes AMD1, TP53INP1, ULK1, 
and NFATC1 are also important in tumorigenesis. AMD1 
and TP53INP1 participate in metabolic pathways, and both 
have tumor suppressor activity (Scuoppo et al., 2012; Saadi 
et al., 2015), whereas ULK1 plays a decisive role in autophagy 
initiation (Zachari and Ganley, 2017) and NFATC1 maintains 
an anergic phenotype in CLL cells (Märklin et al., 2017). 
Finally, two cyclin-dependent kinase genes were recurrently 
deleted: CDK6 and CDK19. Deletions in CDK6 were associated 
with shorter time to first treatment, whereas those in CDK19 
were correlated with a reduced expression of the gene. 
CDK19 is a component of the mediator kinase module, which 
associates with the mediator complex in order to regulate 
diverse cellular functions (Dannappel et al., 2019), and CDK6 
is a promoter of cell-cycle progression (Kollmann and Sexl, 
2013). The role of both genes in the pathogenesis of CLL needs 
further clarification.
Finally, recurrent broad cytogenetic aberrations characteristic 
of CLL were identified at the expected frequency, as in the case 
of trisomy 12, 17p deletion, amplification of 8q, and loss of 8p 
(Blanco et al., 2016). Interestingly, we detected a significant 
adverse time to event and OS effect of trisomy 12 among IGHV-
mutated cases. The importance of IGHV mutation as a predictor 
of disease evolution within the group of patients with trisomy 12 
was previously reported by others (Bulian et al., 2017; Roos-Weil 
et al., 2018), but to our knowledge, this is the first report about the 
prognostic importance of trisomy 12 among IGHV-mutated cases. 
Furthermore, new CNN-LOH events affecting CLL drivers were 
also detected, most of which had not been described in previous 
array-based analysis of the CLL genome (Novak et al., 2002; 
Pfeifer et al., 2007). These CNN-LOH events affected the ATM, 
NOTCH1, TP53, ARID1A, ASXL1, CREBBP, and PI4KB/IL6R loci, 
as well as the telomeric region of 11p. Only part of these mutations 
had concurrent mutations in their corresponding driver genes, 
suggesting the existence of other mechanisms of pathogenicity.
Detection of copy number changes based on exome-
sequencing has been proven to be prone to false positives 
by some studies (Rieber et al., 2017). In this analysis, we 
have included patient matched control samples, we applied 
stringent thresholds in order to minimize false detections, and 
we recapitulated most of the cytogenetic findings of CLL in 
the expected frequency. Furthermore, we could correlate the 
presence of this structural aberrations with changes in gene 
expression in a subgroup of patients, although we believe that 
this study may be underpowered to detect such associations.
In conclusion, our study presents proof-of-concept 
evidence for the existence of new focal recurrent CNAs and 
CNN-LOH in the genome of CLL, some of which influence 
clinical outcome. Furthermore, we observed that some 
of these novel events have significant correlations with 
gene expression changes. The results are concordant with 
the possible involvement of a set of oncogenes and tumor 
suppressors in the development of CLL. These results should 
be considered a “proof of concept,” and their existence and 
functionality should be validated in the future.
FIGURE 3 | Probability of treatment need (A) and survival (B) for trisomy 12-negative patients with mutated IGHV (red line), trisomy 12-positive patients with 
mutated IGHV (blue line), trisomy 12-negative patients with unmutated IGHV (green line), and trisomy 12-positive patients with unmutated IGHV patients 
(purple line).
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TABLE 3 | Significantly enriched broad cytogenetic aberrations in the chronic lymphocytic leukemia (CLL) genome.
Arm Genes Amp frequency Amp frequency 
score
Amp z-score Amp q-value Del frequency Del frequency 
score
Del z-score Del q-value
1p 2,121 0 0 −0.613 0.92 0 0 −0.613 0.93
1q 1,955 0 0 −0.729 0.92 0 0 −0.729 0.93
2p 924 0.02 0.02 6.99 1.81E−11 0 0 0.446 0.93
2q 1,556 0 0 1.16 0.48 0 0 0.106 0.93
3p 1,062 0 0 0.543 0.83 0 0 −1.17 0.93
3q 1,139 0.01 0.01 3.26 3.59E−03 0 0 −1.13 0.93
4p 489 0 0 −1.38 0.92 0 0 0.0708 0.93
4q 1,049 0 0 0.53 0.83 0 0 −1.17 0.93
5p 270 0 0 −0.0742 0.92 0 0 −1.45 0.93
5q 1,427 0 0 0.965 0.59 0 0 −1.01 0.93
6p 1,173 0 0 −1.13 0.92 0 0 −1.13 0.93
6q 839 0 0 −1.25 0.92 0.01 0.01 1.14 0.67
7p 641 0 0 −1.33 0.92 0 0 −0.574 0.93
7q 1,277 0 0 −0.151 0.92 0 0 −0.151 0.93
8p 580 0 0 0.155 0.92 0.01 0.01 3.12 0.01
8q 859 0.01 0.01 3.58 1.36E−03 0 0 −0.433 0.93
9p 422 0 0 −1.4 0.92 0.01 0.01 0.74 0.93
9q 1,113 0 0 −1.15 0.92 0 0 0.594 0.93
10p 409 0 0 −1.41 0.92 0 0 −1.41 0.93
10q 1,268 0 0 −1.08 0.92 0 0 −1.08 0.93
11p 862 0 0 −0.442 0.92 0 0 −0.442 0.93
11q 1,515 0 0 −0.969 0.92 0 0 1.09 0.67
12p 575 0.14 0.14 43.2 0 0 0 −1.26 0.93
12q 1,447 0.14 0.14 58.9 0 0 0 −0.933 0.93
13q 654 0 0 −1.32 0.92 0 0 −1.32 0.93
14q 1,341 0 0 −1.05 0.92 0 0 −0.1 0.93
15q 1,355 0 0 −0.0881 0.92 0 0 −1.05 0.93
16p 872 0 0 −1.24 0.92 0 0 −0.439 0.93
16q 702 0 0 −1.31 0.92 0 0 −0.54 0.93
17p 683 0 0 −1.3 0.92 0.02 0.02 4.8 3.16E−05
17q 1,592 0 0 0.144 0.92 0 0 1.22 0.67
18p 143 0.01 0.01 1.9 0.12 0.02 0.02 3.24 0.01
18q 446 0.01 0.01 2.92 9.84E−03 0 0 −1.39 0.93
19p 995 0.01 0.01 2.16 0.07 0 0 0.492 0.93
19q 1,709 0.01 0.01 3.73 9.33E−04 0 0 1.44 0.64
20p 355 0 0 −0.714 0.92 0.01 0.01 1.39 0.64
20q 753 0 0 −0.51 0.92 0 0 −1.29 0.93
21q 509 0.01 0.01 0.823 0.67 0 0 0.0945 0.93
22q 921 0 0 −1.22 0.92 0 0 0.411 0.93
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